Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP, Human Resources | December 02, 2024 | December 04, 2024 |
| Envista Holdings CorpNVST · Entity 4007 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date December 02, 2024 · Filed December 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,308 |
Ending reported balance
After 2024-12-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-12-02 · Exercise / conversion · Acquired 3,066 · Balance 35,094 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023. Row 2 · 2024-12-02 · Exercise / conversion · Acquired 1,197 · Balance 36,291 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023. Row 3 · 2024-12-02 · Sale · Disposed 6,983 · Balance 29,308 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.26 · Expires 2026-02-22 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-02 · Exercise / conversion · Disposed 3,066 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023. F2: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.55 · Expires 2027-02-28 | Direct | 13,183 |
Reported balance
After 2024-12-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-12-02 · Exercise / conversion · Disposed 1,197 · Balance 13,183 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023. F3: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.
F2: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
F3: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Envista Holdings Corp
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,940 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 9,330 · Balance 59,940 F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2023 Filed Jan 3, 2023 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-000049 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022. Read SEC document |
| December 15, 2022 Filed Dec 15, 2022 23:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,500 | $46.62 | $349,668.00 |
DisclosureSEC source: 0001225208-22-012852 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,413 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.49 to $46.75 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 15, 2022 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,678 | $42.60 | $71,482.80 |
DisclosureSEC source: 0001225208-22-011694 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,913 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:27 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 13,322 | $40.52 | $539,743.49 |
DisclosureSEC source: 0001225208-22-011013 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,591 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.315 to $40.745 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 20:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,500 | $42.21 | $316,585.50 |
DisclosureSEC source: 0001225208-22-010382 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,913 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.133 to $42.28 inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 21:51 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,500 | $42.03 | $315,259.50 |
DisclosureSEC source: 0001225208-22-009534 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,413 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $41.93 to $42.17, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 18, 2022 Filed Jul 18, 2022 20:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,500 | $38.00 | $285,000.00 |
DisclosureSEC source: 0001225208-22-008824 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,913 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 20:27 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,500 | $38.00 | $285,000.00 |
DisclosureSEC source: 0001225208-22-008300 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,413 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 24, 2022 Filed May 31, 2022 20:32 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 4,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-22-000076 · wf-form4_165402910849675.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,650 F1 · shares: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest one year after the grant date. RSUs are payable in shares of common stock on a one-to-one basis. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,500 | $39.43 | $295,725.00 |
DisclosureSEC source: 0001225208-22-007121 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,913 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 14, 2022 Filed Apr 14, 2022 20:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,500 | $44.47 | $333,518.25 |
DisclosureSEC source: 0001225208-22-005838 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,413 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.22 to $44.64, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,500 | $42.34 | $317,586.75 |
DisclosureSEC source: 0001225208-22-004768 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,913 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.14 to $42.59, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003858 · doc4.xml · derivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,630 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 479 | $44.17 | $21,157.43 |
DisclosureSEC source: 0001225208-22-003858 · doc4.xml · nonDerivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,413 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003858 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003858 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,262 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 11,772 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003277 · doc4.xml · derivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,772 Underlying: Common Stock · 11,772 shares Expires 2023-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · balance_after: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003075 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 458 | $42.55 | $19,487.90 |
DisclosureSEC source: 0001225208-22-003075 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,562 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003075 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · derivative · entry 6 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,706 Underlying: Common Stock · 1,853 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 544 | $42.55 | $23,147.20 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · nonDerivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,462 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · nonDerivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · derivative · entry 5 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 2,250 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 661 | $42.83 | $28,310.63 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,153 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 23,455 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · derivative · entry 5 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,455 Underlying: Common Stock · 23,455 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 8,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · derivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,203 Underlying: Common Stock · 8,203 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Underlying: Common Stock · 1,661 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 488 | $44.01 | $21,476.88 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,564 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 5,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000108 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,614 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,832 | $42.48 | $77,823.36 |
DisclosureSEC source: 0001225208-22-000108 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,391 Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000108 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,321 | $40.83 | $135,596.43 |
DisclosureSEC source: 0001225208-21-015058 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,609 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,321 | $42.18 | $140,079.78 |
DisclosureSEC source: 0001225208-21-013896 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,930 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 20:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,322 | $43.58 | $144,772.76 |
DisclosureSEC source: 0001225208-21-013131 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,251 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,321 | $44.88 | $149,046.48 |
DisclosureSEC source: 0001225208-21-012419 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,573 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,322 | $44.30 | $147,164.60 |
DisclosureSEC source: 0001225208-21-011514 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,894 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,321 | $42.42 | $140,876.82 |
DisclosureSEC source: 0001225208-21-010757 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,216 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 20:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,322 | $42.70 | $141,849.40 |
DisclosureSEC source: 0001225208-21-009467 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,537 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:43 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 4,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-21-000079 · wf-form4_162214814161152.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,215 F1 · shares: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the date of the Issuer's 2022 Annual Meeting of Stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the Issuer. RSUs are payable in shares of common stock on a one-to-one basis. F2 · balance_after: Includes 16,185 RSUs that were previously reported in Table II. Read SEC document |
| April 30, 2021 Filed May 3, 2021 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 2,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007382 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,859 Read SEC document |
| April 30, 2021 Filed May 3, 2021 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 13,750 | $43.72 | $601,192.63 |
DisclosureSEC source: 0001225208-21-007382 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,217 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.41 to $43.92, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004214 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630 Underlying: Common Stock · 1,629 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 479 | $38.78 | $18,575.62 |
DisclosureSEC source: 0001225208-21-004214 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,967 Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004214 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 6,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003516 · doc4.xml · derivative · entry 7 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,567 Underlying: Common Stock · 6,567 shares Expires 2022-12-31 F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · balance_after: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003516 · doc4.xml · derivative · entry 6 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,318 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 681 | $39.20 | $26,695.20 |
DisclosureSEC source: 0001225208-21-003516 · doc4.xml · nonDerivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,817 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.